Evidence map›Paper›PMID 27743383›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

LncRNA GAS5 inhibits proliferation and progression of prostate cancer by targeting miR-103 through AKT/mTOR signaling pathway.

Dong Xue, Cuixing Zhou, Hao Lu, Renfang Xu, Xianlin Xu, Xiaozhou He

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Metformin reverses tamoxifen resistance through theAnnals of translational medicine · 2022
    Article
  11. Review
  12. Long non-coding RNA in prostate cancer.American journal of clinical and experimental urology · 2022
    Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Dong XueDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China.
Cuixing ZhouDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China.
Hao LuDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China.
Renfang XuDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China.
Xianlin XuDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China.
Xiaozhou HeDepartment of Urology, Third Affiliated Hospital, Suzhou University, No. 185 Juqian Street, Changzhou, Jiangsu, 213003, China. xxhehexz@163.com.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In prior research, evidence has been found for a relation between low exposure of long non-coding RNAs (lncRNAs) and prostate tumor genesis. This study aims to clarify the underlying mechanisms of lncRNA GAS5 in prostate cancer (PCa). In total, 118 pairs of PCa tissues and matched adjacent non-tumor tissues were collected. Additionally, lncRNA GAS5 exposure levels were determined using RT-PCR and in situ hybridization. In addition, dual-luciferase report assay was performed to verify the target effect of lncRNA GAS5 on miR-103. The exposure levels of the proteins related to the protein kinase B (AKT)/mammalian target of rapamycin (mTOR) axis, including AKT, mTOR, and S6K1, were measured by western blot PC3 cells infected with lncRNA GAS5 mimic; lncRNA GAS5 siRNA; or a combination of lncRNA and miR-103. The proliferation, invasion, and migration ability of PC3 cells after being infected were tested by MTT assay, wound healing assay, and transwell assays. Finally, nude mouse xenograft models were used to measure lncRNA GAS5 effects on prostate tumor growth in vivo. The lncRNA GAS5 levels were reduced significantly in the PCa tissues and cell lines (P < 0.05). A low exposure of lncRNA GAS5 caused AKT/mTOR signaling pathway activation in PC3 cells (P < 0.05). In addition, over-exposure of lncRNA GAS5 was proven to significantly decelerate PCa cell progression in vitro and tumor growth in vivo through inactivating the AKT/mTOR signaling pathway (P < 0.05). This study proves that lncRNA GAS5 plays a significant role in the decelerating PCa development via mediating the AKT/mTOR signaling pathway through targeting miR-103.

Indexed as

AKT/mTOR signaling pathwayInvasionLncRNA GAS5MigrationmiR-103ProliferationProstate cancerXenograft model

Identifiers

PMID27743383
OpenAlexW2530295635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.